(Q28237341)

1

0 references

E-U Graefe

2

0 references

P Tanswell

3

0 references

A M Scott

4

0 references

R Hofheinz

5

0 references

A Amelsberg

Investigational New Drugs

6

0 references

language of work or name

English

0 references

publication date

January 2004

0 references

published in

0 references

volume

22

0 references

issue

1

0 references

page(s)

39-52

0 references

cites work

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers

1 reference

12 December 2020

Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients

1 reference

12 December 2020

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

12 December 2020

Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33

1 reference

12 December 2020

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

12 December 2020

Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue

1 reference

12 December 2020

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

12 December 2020

Fibroblast activation protein: purification, epitope mapping and induction by growth factors

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

1 reference

12 December 2020

Metabolic properties of IgG subclasses in man

1 reference

12 December 2020

Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer

1 reference

12 December 2020

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Assessment of actual significance levels for covariate effects in NONMEM.

1 reference

12 December 2020

Increasing the serum persistence of an IgG fragment by random mutagenesis.

1 reference

12 December 2020

Metabolism of immunoglobulins

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection

1 reference

12 December 2020

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

1 reference

12 December 2020

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers

1 reference

12 December 2020

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers

1 reference

12 December 2020

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

1 reference

12 December 2020

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

1 reference

12 December 2020

Pharmacokinetics of indium-111-labeled B72.3 monoclonal antibody in colorectal cancer patients

1 reference

12 December 2020

Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients

1 reference

12 December 2020

Blood vessel formation: what is its molecular basis?

1 reference

12 December 2020

Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers

1 reference

12 December 2020

Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model

1 reference

12 December 2020

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

12 December 2020

Automated covariate model building within NONMEM.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.

1 reference

12 December 2020

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer

1 reference

12 December 2020

Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.

1 reference

12 December 2020

Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts

1 reference

12 December 2020

Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts

1 reference

12 December 2020

A perspective of monoclonal antibodies: past, present, and future

1 reference

12 December 2020

A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation

1 reference

12 December 2020

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation.

1 reference

12 December 2020